- Home
- AKBA vs IIM Comparison
AKBA vs IIM Comparison
Compare AKBA & IIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- IIM
- Stock Information
- Founded
- AKBA 2007
- IIM 1993
- Country
- AKBA United States
- IIM United States
- Employees
- AKBA N/A
- IIM N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- IIM Investment Managers
- Sector
- AKBA Health Care
- IIM Finance
- Exchange
- AKBA Nasdaq
- IIM Nasdaq
- Market Cap
- AKBA 669.7M
- IIM 551.6M
- IPO Year
- AKBA 2014
- IIM N/A
- Fundamental
- Price
- AKBA $3.69
- IIM $11.66
- Analyst Decision
- AKBA Strong Buy
- IIM
- Analyst Count
- AKBA 5
- IIM 0
- Target Price
- AKBA $6.90
- IIM N/A
- AVG Volume (30 Days)
- AKBA 6.0M
- IIM 122.2K
- Earning Date
- AKBA 05-08-2025
- IIM 01-01-0001
- Dividend Yield
- AKBA N/A
- IIM 4.63%
- EPS Growth
- AKBA N/A
- IIM N/A
- EPS
- AKBA N/A
- IIM 0.02
- Revenue
- AKBA $184,909,000.00
- IIM N/A
- Revenue This Year
- AKBA $23.32
- IIM N/A
- Revenue Next Year
- AKBA $49.90
- IIM N/A
- P/E Ratio
- AKBA N/A
- IIM $591.50
- Revenue Growth
- AKBA N/A
- IIM N/A
- 52 Week Low
- AKBA $0.80
- IIM $9.94
- 52 Week High
- AKBA $3.73
- IIM $12.32
- Technical
- Relative Strength Index (RSI)
- AKBA 83.69
- IIM 44.29
- Support Level
- AKBA $2.76
- IIM $11.61
- Resistance Level
- AKBA $3.73
- IIM $11.75
- Average True Range (ATR)
- AKBA 0.18
- IIM 0.08
- MACD
- AKBA 0.07
- IIM -0.01
- Stochastic Oscillator
- AKBA 96.67
- IIM 24.56
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About IIM Invesco Value Municipal Income Trust
Invesco Value Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide common shareholders with current income which is exempt from federal income tax.